Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and PTC Therapeutics, Inc.

SG&A Expenses: PTC vs. Pharming Over a Decade

__timestampPTC Therapeutics, Inc.Pharming Group N.V.
Wednesday, January 1, 2014448200004042025
Thursday, January 1, 2015820800005279557
Friday, January 1, 2016971300008073913
Sunday, January 1, 201712127100044864073
Monday, January 1, 201815354800053488904
Tuesday, January 1, 201920254100065896361
Wednesday, January 1, 202024516400069968267
Friday, January 1, 202128577300092047281
Saturday, January 1, 2022325998000131819000
Sunday, January 1, 202333254000087501000
Loading chart...

Data in motion

A Decade of SG&A: Pharming Group N.V. vs. PTC Therapeutics, Inc.

In the competitive landscape of the pharmaceutical industry, operational efficiency is key. Over the past decade, PTC Therapeutics, Inc. has consistently outpaced Pharming Group N.V. in Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, PTC Therapeutics saw a staggering 642% increase in SG&A costs, peaking in 2023. In contrast, Pharming Group N.V. experienced a more modest 206% rise over the same period.

This trend highlights PTC Therapeutics' aggressive expansion and investment in operational infrastructure, while Pharming Group N.V. has maintained a more conservative approach. The year 2022 marked a significant milestone for Pharming, with SG&A expenses reaching their highest at 131.8 million, a 46% increase from the previous year. As these companies navigate the complexities of the pharmaceutical market, their SG&A strategies offer a window into their broader business objectives.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025